Keratinocyte RIPK3 climbs with psoriasis severity — and ablating it in mice cuts S100A8/A9 output and skin damage, a new mechanistic study shows.

The work, led by Changjun Song, Yiqun Zhang, Zizhen Zhou, and colleagues at the Institute of Dermatology, Chinese Academy of Medical Sciences, ties the kinase to calprotectin's inflammatory feedback loop. It runs through STAT1, not the canonical necroptosis partner MLKL. The team frames RIPK3 as a candidate target sitting upstream of IL-17A's downstream damage signals.

What did the team see in patient skin?

They started with biopsies from five psoriasis patients and five healthy controls, drawn from the Jiangsu Biobank of Clinical Resources. RIPK3 protein ran high in lesional epidermis compared with normal skin. Two public RNA-sequencing datasets — GSE13355 and GSE173706 — confirmed the bump at mRNA level. Single-cell sequencing pinned the source to keratinocytes. Disease severity tracked RIPK3 levels in patient tissue, the authors report.

What happened in the mouse models?

The group ran imiquimod and IL-23 psoriasiform dermatitis models side by side — two of the field's standard induction routes. Mice engineered to lack RIPK3 specifically in keratinocytes showed milder skin damage in both models. Epidermal S100A8/A9 protein dropped with the knockout. The pattern held across two chemically distinct induction pathways, which strengthens the read.

How does the kinase drive S100A8/A9?

In human keratinocytes stimulated with IL-17A, RIPK3 knockdown curbed proliferation and calprotectin release. STAT1 emerged as the required transcription factor. MLKL, the canonical necroptosis effector downstream of RIPK3, did not. The kinase amplifies calprotectin output through a signaling molecule the field already studies. Its role here sits outside its cell-death job — a key wrinkle the authors flag.

Can the loop be rescued?

Yes, and cleanly. Give recombinant S100A8/A9 back to the keratinocyte-specific RIPK3-knockout mice and psoriasiform dermatitis returns. Skin thickens. Inflammation comes back. The proof-of-rescue anchors the chain the authors propose: IL-17A → RIPK3 → STAT1 → S100A8/A9. Cut any link and the loop stutters. Re-add calprotectin and it revives.

Why this pathway matters

IL-17A sits atop the modern psoriasis treatment stack. Chronic inflammation, though, depends on a feedback loop with DAMPs like calprotectin — the S100A8/A9 heterodimer — and that loop keeps the disease simmering between doses. Disrupting the loop has long appealed to drug hunters looking past cytokine blockers. This study puts a specific kinase upstream of the loop and shows STAT1 carries the message. The paper names no clinical candidate. It does hand researchers a sharper target and a cleaner rescue story than most preclinical psoriasis work.

Where this sits today

RIPK3 remains firmly in the preclinical bucket for now. Funders include the National Natural Science Foundation of China (grant 82404167) and the CAMS Innovation Fund for Medical Sciences (2023-I2M-C&T-B-111). Ethics approval came from the Medical Ethics Committee at the Institute of Dermatology (approval 2017-KY-022). The authors declared no competing financial interests.

The takeaway in plain words: psoriasis research keeps building a target map around keratinocyte signaling, and RIPK3 just earned its pin on it.